1. Home
  2. ZLAB vs TWST Comparison

ZLAB vs TWST Comparison

Compare ZLAB & TWST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ZLAB
  • TWST
  • Stock Information
  • Founded
  • ZLAB 2013
  • TWST 2013
  • Country
  • ZLAB China
  • TWST United States
  • Employees
  • ZLAB N/A
  • TWST N/A
  • Industry
  • ZLAB Biotechnology: Pharmaceutical Preparations
  • TWST Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • ZLAB Health Care
  • TWST Health Care
  • Exchange
  • ZLAB Nasdaq
  • TWST Nasdaq
  • Market Cap
  • ZLAB 3.0B
  • TWST 2.7B
  • IPO Year
  • ZLAB 2017
  • TWST 2018
  • Fundamental
  • Price
  • ZLAB $26.85
  • TWST $47.19
  • Analyst Decision
  • ZLAB Strong Buy
  • TWST Buy
  • Analyst Count
  • ZLAB 4
  • TWST 9
  • Target Price
  • ZLAB $52.50
  • TWST $52.33
  • AVG Volume (30 Days)
  • ZLAB 960.6K
  • TWST 786.5K
  • Earning Date
  • ZLAB 11-12-2024
  • TWST 01-31-2025
  • Dividend Yield
  • ZLAB N/A
  • TWST N/A
  • EPS Growth
  • ZLAB N/A
  • TWST N/A
  • EPS
  • ZLAB N/A
  • TWST N/A
  • Revenue
  • ZLAB $355,748,000.00
  • TWST $312,974,000.00
  • Revenue This Year
  • ZLAB $48.50
  • TWST $21.97
  • Revenue Next Year
  • ZLAB $47.37
  • TWST $18.69
  • P/E Ratio
  • ZLAB N/A
  • TWST N/A
  • Revenue Growth
  • ZLAB 35.01
  • TWST 27.69
  • 52 Week Low
  • ZLAB $13.48
  • TWST $27.41
  • 52 Week High
  • ZLAB $36.60
  • TWST $60.90
  • Technical
  • Relative Strength Index (RSI)
  • ZLAB 45.71
  • TWST 49.60
  • Support Level
  • ZLAB $25.85
  • TWST $46.56
  • Resistance Level
  • ZLAB $29.87
  • TWST $49.75
  • Average True Range (ATR)
  • ZLAB 1.05
  • TWST 2.36
  • MACD
  • ZLAB -0.18
  • TWST -0.42
  • Stochastic Oscillator
  • ZLAB 21.98
  • TWST 8.57

About ZLAB Zai Lab Limited

Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-2306 for treatments across multiple solid tumor types including ovarian and certain types of breast and lung cancers; ZL-2401 which is an antibiotic in a new class of tetracycline derivatives; and ZL-2301 is an oral, small molecule which targets HCC.

About TWST Twist Bioscience Corporation

Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well-plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies and powers cost-effective, rapid high-throughput synthesis, enabling researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of its revenue from the United States.

Share on Social Networks: